ADOCIA SAS (ADOC.PA) Stock Price, Forecast & Analysis
EPA:ADOC • FR0011184241
ADOC.PA Key Statistics, Chart & Performance
The current stock price of ADOC.PA is 6.38 EUR. In the past month the price increased by 5.45%. In the past year, price increased by 19.25%.
ADOC.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ADOC.PA. When comparing the yearly performance of all stocks, ADOC.PA is a bad performer in the overall market: 76.74% of all stocks are doing better.
ADOC.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADOC.PA. ADOC.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ADOC.PA Financial Highlights
Over the last trailing twelve months ADOC.PA reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 63.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.67% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ADOC.PA Forecast & Estimates
9 analysts have analysed ADOC.PA and the average price target is 15.5 EUR. This implies a price increase of 143.01% is expected in the next year compared to the current price of 6.38.
For the next year, analysts expect an EPS growth of -84.23% and a revenue growth -51.75% for ADOC.PA
ADOC.PA Ownership
ADOC.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 28.02 | 43.529B | ||
| ARGX | ARGENX SE | 28.07 | 43.504B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.617B | ||
| ABVX | ABIVAX SA | N/A | 8.158B | ||
| 2X1 | ABIVAX SA | N/A | 7.695B | ||
| GXE | GALAPAGOS NV | N/A | 1.868B | ||
| GLPG | GALAPAGOS NV | N/A | 1.866B | ||
| 6IV | INVENTIVA SA | N/A | 1.034B | ||
| IVA | INVENTIVA SA | N/A | 1.008B | ||
| NANO | NANOBIOTIX | N/A | 994.371M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ADOC.PA
Company Profile
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 77 full-time employees. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
Company Info
ADOCIA SAS
115 avenue Lacassagne
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 76
Phone: 33472610610
ADOCIA SAS / ADOC.PA FAQ
What does ADOC do?
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 77 full-time employees. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
What is the stock price of ADOCIA SAS today?
The current stock price of ADOC.PA is 6.38 EUR. The price increased by 2.74% in the last trading session.
What is the dividend status of ADOCIA SAS?
ADOC.PA does not pay a dividend.
How is the ChartMill rating for ADOCIA SAS?
ADOC.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for ADOCIA SAS?
ADOCIA SAS (ADOC.PA) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of ADOC stock?
ADOCIA SAS (ADOC.PA) has a market capitalization of 116.82M EUR. This makes ADOC.PA a Micro Cap stock.